Lecicarbon Dospelí (Sodium Hydrogen Carbonate, Sodium Dihydrogen Phosphate)

Sodium hydrogen carbonate dissociates to release bicarbonate ions, which combine with hydrogen ions present in the rectal environment. This reaction raises the local pH, neutralizing acidity and creating a more physiologic condition that supports diagnostic imaging and therapeutic interventions.

The dose of Lecicarbon Dospelí is determined by the prescribing healthcare professional based on the specific clinical situation, patient characteristics, and intended use. No fixed regimen is provided in public literature.

Safety data are limited. Use during pregnancy or lactation should only occur if the potential benefit justifies any potential risk, and it must be prescribed by a qualified clinician who can evaluate the individual circumstances.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with standard saline or plain water enemas, Lecicarbon Dospelí provides a defined buffering capacity that more effectively neutralizes acidic conditions. This can improve patient comfort and procedural outcomes, although the choice of agent depends on the clinical protocol and physician preference.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The preparation is introduced rectally, typically using a suitable applicator or enema device as directed by the healthcare provider. Administration techniques follow standard rectal delivery practices to ensure even distribution of the buffering solution.

Serious risks include electrolyte imbalance (especially sodium or phosphate disturbances), severe allergic reactions, unexpected rectal bleeding, and metabolic alkalosis if excessive buffering occurs. Patients should be monitored for these events, particularly when used with other alkalinizing agents.

Individuals with known hypersensitivity to sodium hydrogen carbonate, sodium dihydrogen phosphate, or any component of the formulation should avoid it. Patients with uncontrolled electrolyte disorders, severe renal impairment, or those taking high‑dose systemic alkalinizing drugs should also be excluded unless a physician determines it is safe.